Cape Ann Savings Bank buys $922,136 stake in Abbott Laboratories (ABT)

Abbott Laboratories (ABT) : Cape Ann Savings Bank scooped up 60 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 19, 2016. The investment management firm now holds a total of 21,621 shares of Abbott Laboratories which is valued at $922,136.Abbott Laboratories makes up approximately 1.23% of Cape Ann Savings Bank’s portfolio.

Other Hedge Funds, Including , Tnb Financial boosted its stake in ABT in the latest quarter, The investment management firm added 80 additional shares and now holds a total of 30,256 shares of Abbott Laboratories which is valued at $1,290,418. Abbott Laboratories makes up approx 0.33% of Tnb Financial’s portfolio.Gateway Investment Advisers boosted its stake in ABT in the latest quarter, The investment management firm added 1,008 additional shares and now holds a total of 1,271,318 shares of Abbott Laboratories which is valued at $53,357,216. Abbott Laboratories makes up approx 0.45% of Gateway Investment Advisers’s portfolio.Menlo Advisors boosted its stake in ABT in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 48,742 shares of Abbott Laboratories which is valued at $2,045,702. Abbott Laboratories makes up approx 1.71% of Menlo Advisors’s portfolio.Vontobel Asset Management Inc boosted its stake in ABT in the latest quarter, The investment management firm added 1,266,683 additional shares and now holds a total of 4,554,305 shares of Abbott Laboratories which is valued at $191,144,181. Abbott Laboratories makes up approx 1.56% of Vontobel Asset Management Inc’s portfolio.

Abbott Laboratories opened for trading at $42.8 and hit $42.92 on the upside on Wednesday, eventually ending the session at $42.65, with a gain of 2.03% or 0.85 points. The heightened volatility saw the trading volume jump to 1,36,86,493 shares. Company has a market cap of $62,659 M.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Abbott Laboratories - Is it time to Sell?

Top Brokerage Firms are advising their investors on Abbott Laboratories. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.